The Precision
Oncology Company
About us
The Precision
Oncology Company
PANGAEA ONCOLOGY is a translational precision oncology company integrating molecular diagnostics, clinical research, and preclinical modeling to generate actionable insights directly from real patient data.
PANGAEA ONCOLOGY IN FIGURES
PATIENTS
VISITS
ACTS
TRIALS
CLIENTS
(FTE)
OUR CORE COMMITMENTS
PANGAEA ONCOLOGY’s mission is to change the natural history of the disease, improving the survival of cancer patients, through the application of the best professionals and technologies.
We operate at the intersection of clinical practice and advanced laboratory capabilities, enabling a seamless connection between patient samples, biomarker discovery, and therapeutic decision-making.
Our expertise spans next-generation sequencing (NGS) in both tissue samples and liquid biopsy, transcriptomics, and functional validation models, positioning us as a leading partner in precision oncology and clinical trial support.
OUR SERVICES
Molecular diagnostics
Fast, accurate molecular diagnostics for tissue and liquid biopsy. Our ISO 15189-accredited laboratory offers comprehensive genomic and biomarker testing using NGS, IHC, FISH, RT-PCR and nCounter to support diagnosis, treatment decisions and clinical trial eligibility.
DX platforms Validation
Reference laboratory services for analytical and clinical validation of molecular diagnostic assays. We support companion diagnostic development with standardized workflows, regulatory-grade quality and proven experience in diagnostic kit validation.
Pre-clinical services:
PANGAEA LAB combines advanced molecular diagnostics with preclinical cancer research to generate clinically relevant insights. Our capabilities include biomarker discovery, in vitro testing, patient-derived primary cultures, drug-resistance models and organoid-based approaches for translational oncology projects.
CLINICAL TRIAL LAB SERVICES
Central lab services for global and multicenter trials, with real-time molecular screening, patient stratification and biomarker analysis. PANGAEA has served as central laboratory in more than 15 liquid biopsy clinical trials.
our latest news & publications
- All Post
- Instituto Oncológico Rosell
- International Breast Cancer Center
- Pangaea Lab
- Pangaea Oncology
- Quénet Torrent Institute
The HUSC Oncology Innovation Cancer Center, will concentrate three interrelated activities in the same space to combat cancer: medical assistance, innovation, and a unit for clinical trials to test innovative oncological...
The study that demonstrates this has been presented at the AACR congress and is the result of the shared leadership of the scientists of Pangaea Lab, one of the centers with...
Rafael Rosell, world expert in lung cancer. "Avoiding adaptive resistance would be the beginning of controlling tumor clinical progression, since it would control acquired resistance. A challenge in lung cancer."